Recurrent Status Epilepticus and SARS-CoV-2 infection: the “perfect storm”

Main Article Content

Giada Pauletto
Annacarmen Nilo
Cristian Deana
Lorenzo Verriello
Ilaria Del Negro
Christian Lettieri
Luigi Vetrugno
Mariarosaria Valente
Gian Luigi Gigli


status epilepticus, delirium, anti-seizure medications, EEG monitoring, SARS-CoV-2


Respiratory involvement is the most common clinical manifestation of COVID-19, but neurological symptoms and complications are increasingly being recognized. Seizures and status epilepticus (SE) have been described as possible consequences of hypoxia and metabolic derangements during SARS-CoV-2 infection, direct viral invasion of the central nervous system, or as para or post-infectious complications. Single episodes of SE have been described, occurring during the acute phase of COVID-19 or once the patients have been recovered.

Herein, we present the case of a patient with a positive serology test for SARS-CoV-2 (IgG+, IgM-) and recurrent SE occurring within 36 days. Diagnostic work-up ruled out other known causes of SE. A post-COVID-19 infectious inflammatory/immune response is hypothesized as the possible trigger of SE.


Download data is not yet available.
Abstract 456 | PDF Downloads 180


1. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet 2020; 19(9): 767-83. Doi: 10.1016/S1474-4422(20)30221-0.
2. Deana C, Verriello L, Pauletto G, et al. Insights into neurological dysfunction of critically ill COVID-19 patients. Trends Anaesthesia Critic Care 2020; In press. Doi: 10.1016/j.tacc.2020.09.005.
3. Gigli GL, Vogrig A, Nilo A, et al. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurol Sci 2020; 41(12): 3391-4. Doi: 10.1007/s10072-020-04787-7.
4. Carroll E, Neumann H, Aguero-Rosenfeld ME, et al. Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus. Epilepsia 2020; 61(10): e135-e139. Doi: 10.1111/epi.16683.
5. Vollono C, Rollo E, Romozzi M, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure 2020; 78: 109-112. Doi: 10.1016/j.seizure.2020.04.009.
6. Dono F, Carrarini C, Russo M, et al. New-onset refractory status epilepticus (NORSE) in post SARS-CoV-2 autoimmune encephalitis: a case report. Neurol Sci 2021; 42(1): 35-38. Doi: 10.1007/s10072-020-04846-z.
7. Chen W, Toprani S, Werbaneth K, Falco-Walter J. Status epilepticus and other EEG findings in patients with COVID-19: a case series. Seizure 2020; 81: 198-200. Doi: 10.1016/j.seizure.2020.08.022.
8. Somani S, Pati S, Gaston T, Chitlangia A, Agnihotri S. De novo status epilepticus in patients with COVID-19. Ann Clin Transl Neurol 2020; 7(7): 1240-4. Doi: 10.1002/can.3.51071.
9. Balloy G, Leclair-Visonneau L, Péréon Y, Magot A, Peyre A, Mahé PJ, et al. Non-lesional status epilepticus in a patient with coronavirus disease 2019. Clin Neurophysiol 2020; 131(8): 2059-61. Doi: 10.1016/j.clinph.2020.05.005.
10. Pilotto A, Odolini S, Masciocchi S, et al. Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol 2020; 88(2): 423-7. Doi: 10.1002/ana.25783.
11. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLos One 2020; 15(12): e0242958. Doi: 10.1371/journal.pone.0242958.
12. Hosseini AA, Shetty AK, Sprigg N, Auer DP, Constantinescu CS. Delirium as a presenting feature in COVID-19: neuroinvasive infection or autoimmune encephalopathy? Brain Behav Immun 2020; 88: 68-70. Doi: 10.1016/j.bbi.2020.06.012.

Most read articles by the same author(s)

1 2 > >>